scholarly journals Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report

2014 ◽  
Vol 54 (4) ◽  
pp. 327-330 ◽  
Author(s):  
Takeo ANDA ◽  
Masaru HONDA ◽  
Tokuhiro ISHIHARA ◽  
Toshiaki KAMEI
2019 ◽  
Vol 26 (4) ◽  
pp. 1029-1031 ◽  
Author(s):  
Gorkem Turkkan ◽  
Caner Dogan ◽  
Burak Tek

Introduction Bicalutamide is widely used in the treatment of prostate cancer. Among its side effects, central nervous system disorders are relatively rare, and the information about bicalutamide-associated hallucinations is limited. Case report We report an uncommon case of a patient with metastatic prostate cancer, who had hallucinations due to the use of bicalutamide. Management and outcome The patient accepted to receive only hormonal therapy (bicalutamide and leuprolide acetate). But he developed hallucinations due to bicalutamide use. His hallucinations disappeared after discontinuation of bicalutamide. A good response was obtained with the use of luteinizing hormone-releasing hormone agonist monotherapy. Discussion The pathophysiology of bicalutamide-induced hallucinations is unclear. We hypothesize that antiandrogens can indirectly cause hallucinations through changes in plasma testosterone and cerebral reelin expression. Additionally, luteinizing hormone-releasing hormone agonist monotherapy is a good option in metastatic prostate cancer patients who have intolerable side effects due to the use of antiandrogens.


Author(s):  
Lütfi Canat ◽  
Akif Erbin ◽  
Hasan Tahsin Gözdaş ◽  
Hasan Anıl Atalay

2018 ◽  
Vol 56 ◽  
pp. 2 ◽  
Author(s):  
N. Koutsouvelis ◽  
G. Dipasquale ◽  
A. Dubouloz ◽  
M. Jaccard ◽  
R. Miralbell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document